HOME >> MEDICINE >> NEWS
NIAID Stops AIDS Study Prematurely Because Drug 'Cocktail' Boosts Survival

dicine and director of the AIDS unit; Dr. David Wohl, research fellow in medicine; and research clinician Janet Groves.

Nationwide, researchers found 63 "disease progression events" -- including AIDS-related illnesses and deaths among patients receiving a combination of ZDV and 3TC, Eron said. Among patients receiving those two drugs and indinavir, they found only 33 such events.

"There were 18 deaths in the double-therapy arm of the study vs. eight deaths in the triple- therapy arm," he said. "No major differences were found in either safety or toxicity between the two treatments, and study medications were well-tolerated."

Indinavir, a protease inhibitor, works by preventing protease enzymes from cutting up proteins needed to form viruses, Eron explained. The envelope, or outer coating, of the virus still develops, but the core cannot, and therefore the resulting virus is not infectious.

Drugs such as ZDV and 3TC work by inhibiting an enzyme called reverse transcriptase. That enzyme enables the virus' genetic material, or RNA, to convert human genetic material known as DNA into more virus.

The Food and Drug Administration approved use of the combined ZDV and 3TC in November 1995, in part because of a national study Eron led and published in the New England Journal of Medicine. Indinavir has been approved for about a year.

"The people who should be thanked and congratulated for this study and others like it are the people who participated in the trials," Eron said. "They not only have done something that will improve their own care, but they have volunteered to do something that will clearly improve the care of many patients afterwards.

"Treatment with the triple-drug therapy is not easy because of the large number of pills patients have to take and the commitment they have to make to stick to the therapy," he said. "They are the real heroes here."

Glaxo-Wellcome Inc. of Research Triangle Park
'"/>

Contact: David Williamson
rdtokids@email.unc.edu
919-962-2091
University of North Carolina at Chapel Hill
25-Feb-1997


Page: 1 2 3

Related medicine news :

1. NIAID initiates trial of experimental avian flu vaccine
2. NIAID seeks applicants to lead clinical trials units for revamped HIV/AIDS networks
3. NIAID begins enrolling volunteers for novel HIV vaccine study
4. NIAID-sponsored clinical trial aims to boost flu vaccine supply
5. NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks
6. NIAID launches influenza genome sequencing project
7. NIAID launches program to improve medical tools against emerging infectious diseases
8. NIAID forms network to tackle potentially fatal reaction to smallpox vaccine
9. NIAID rotavirus vaccine licensed for commercialization
10. Second NIAID SARS vaccine candidate helps mice fend off SARS
11. NIAID vaccine protects against SARS virus infection in mice

Post Your Comments:
(Date:8/20/2014)... 20, 2014 According to a ... "Multiplexed Diagnostics Market (Technologies: Very High, High, Medium, ... Disease Diagnosis, Oncology, Autoimmune Diseases, Cardiac, Allergies and ... Trends and Forecast, 2013 - 2019", the global ... billion in 2012 and is expected to grow ...
(Date:8/20/2014)... commemorate the 100th anniversary of a revolutionary technique that ... News (C&EN) magazine last week released a special ... a tantalizing glimpse of its future. C&EN is the ... the world,s largest scientific society. , The technique got ... the first paper on X-ray diffraction from a crystal ...
(Date:8/20/2014)... 2014 Transrectal ultrasound guided biopsy is the gold ... suggested that the number of risks associated with the ... Swedish researchers found that six percent of men filled ... within 30 days after having a prostate biopsy, with ... reports The Journal of Urology . , Earlier ...
(Date:8/20/2014)... August 20, 2014 According ... by Type (Acrylonitrile butadiene styrene, Fluor polymer, ... Applications and Geography - Trends & Forecasts ... engineering plastics market with analysis and forecasting ... also identifies the driving and restraining factors ...
(Date:8/20/2014)... August 20, 2014 Ticket Down is ... in Miami, FL at the Sun Life Stadium in early September. ... this September when Brazil and Colombia meet at Sun Life Stadium ... top 10 teams in the world and will be a rematch ... The match will kick-off on Sept. 5 and will feature some ...
Breaking Medicine News(10 mins):Health News:Multiplexed Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Multiplexed Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Multiplexed Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Severe infections with hospitalization after prostate biopsy rising in Sweden 2Health News:Engineering Plastics Market Worth $79,026.6 Million by 2018 – New Report by MarketsandMarkets 2Health News:Engineering Plastics Market Worth $79,026.6 Million by 2018 – New Report by MarketsandMarkets 3Health News:Engineering Plastics Market Worth $79,026.6 Million by 2018 – New Report by MarketsandMarkets 4Health News:Brazil vs. Colombia Tickets in Miami, FL: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Match 2Health News:Brazil vs. Colombia Tickets in Miami, FL: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Match 3
(Date:8/20/2014)... Aug. 20, 2014  Quantum Materials Corporation (OTCQB:QTMM) ... of patent families from Bayer Technology Services GmbH, the ... Bayer AG of Leverkusen, Germany ... broad intellectual property protection for advances Quantum ... dot (QD) manufacturing. In addition, the Bayer patents ...
(Date:8/20/2014)... 20, 2014 Phase I Trial ... US  KalVista Pharmaceuticals ("KalVista"), an ophthalmology company ... announces that it has begun a Phase I, First ... KVD001, for the treatment of DME. The study,s Principal ... Eye Institute, Joslin Diabetes Center; Harvard Medical School Department ...
(Date:8/19/2014)... Ala. , Aug. 19, 2014  The Alabama Supreme ... that patients can sue drug makers who mislead doctors into ... harmful side‑effects.  The case is Weeks v. Wyeth, and the ... makers in that same case last year. Heninger Garrison Davis ... represent the patient in the case, Danny Weeks . ...
Breaking Medicine Technology:Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 2Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 4KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4
Cached News: